Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, an ASX-listed biotech firm specializing in repurposing drugs for neurodegenerative diseases, has announced its Annual General Meeting (AGM) to be held on September 30, 2024, with a director nominations deadline of August 12, 2024. The company recently reported positive Phase 1 study results for their drug targeting ALS and is preparing for a pivotal trial anticipated to start in Q4 2024, potentially leading to expedited FDA approval by 2026.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
